Last update Jan. 24, 2017
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Flavoxate Hydrochloride in other languages or writings:
Flavoxate Hydrochloride belongs to this group or family:
Main tradenames from several countries containing Flavoxate Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 100 | % |
Molecular weight | 428 | daltons |
VD | 2.9 | l/Kg |
Tmax | 1 - 2 | hours |
T½ | 3.5 - 10 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Anticholinergic and smooth-muscle relaxant with antimuscarinic action which is used to relieve spasticity, inflammation, pain and incontinence of the urine bladder tract.
At latest update relevant published data on its excretion into breast milk were not found.
The antimuscarinic effect may reduce milk production (De Martino 1980, Bizarro 1980), albeit only during the first weeks postpartum.
Side effects occur very rarely with a rather low risk during lactation when timely used. Monitoring of milk production and anticholinergic symptoms in the infant such as irritability, nausea or constipation would be desirable.
Until more published data on this drug related to breastfeeding is available, an alternative with a known pharmacokinetic profile that should appear safer while breastfeeding (higher protein-binding capacity, lower half-life span and lower oral bioavailability) may be preferable, especially during the neonatal period and in case of prematurity.